Synthesis and Bioactivity of Furoxan-Based Nitric Oxide-Releasing Colchicine Derivatives as Anticancer Agents

LI HONG SHEN^{1,*}, SHENG LI WANG¹, HONG YU LI¹, YI SHENG LAI² and LI JIE LIU³

¹Handan Key Laboratory of Organic Small Molecule Materials, Handan College, Handan 056005, P.R. China

²Center of Drug Discovery, China Pharmaceutical University, Nanjing 210009, P.R. China

³Hebei Yiling Medicine Corporation Ltd, Shijiazhuang 050035, P.R. China

*Corresponding author: E-mail: latishen@sohu.com

(Received: 21 February 2012;

Accepted: 17 December 2012)

AJC-12570

A series of novel nitric oxide-donating colchicine derivatives (**9a-j**) were synthesized by coupling furoxan with N-methyl colchiceinamide through an appropriate spacer arm and their cytotoxicity against four human cancer cell lines *in vitro* were evaluated by MTT method. It was found that many of the derivatives displayed significant activity, particularly, compound **9f** showed more potent cytotoxic activities than colchicine.

Key Words: Nitric oxide-donating colchicine derivatives, N-Methyl colchiceinamide, Furoxan, Cytotoxicity.

INTRODUCTION

Colchicine (Col, **1**), a major alkaloid extracted from the seed of *Colchicum autumnale* and *Gloriosa superba*, is a drug interfering with microtubule assembly both *in vivo* and *in vitro*, thereby causing cells to accumulate in mitotic arrest during the cell cycle^{1,2}. Colchicine has antiinflammatory, antimitotic and antifibrotic activity³. Colchicine also finds applications in various other diseases like pseudogout, familial Mediterranean fever, tumor growth, cirrhosis of the liver and bile and amyloidosis^{4,5}. Although colchicine is a potent antimitotic agent, its medicinal uses are limited due to its high toxicity. Therefore, many attempts have been made to discover more effective and less toxic analogues of colchicine by modifying the substituents of its basic structure⁶. N-Methyl colchiceinamide (**2**, **Scheme-I**), a synthetic derivative of colchicine, wherein the 10-methoxy group is replaced by a 10-methylimino group, showed considerably higher stability toward acid hydrolysis and is a slightly less active antitumor and toxicity agent than colchicine⁴.

Nitric oxide (NO), naturally synthesized from L-arginine by the action of NO synthase (NOS), is a small, diffusible, highly reactive molecule involved in the regulation of many physiological processes including blood vessel dilatation, neurotransmission and events of the immune system. Nitric oxide can also be generated from synthetic NO-releasing compounds, such as nitrate, furoxan, hydroxyguanidine, S-nitrosothiol, diazeniumdiolate and others^{7,8}. Studies showed

that high concentration of NO was cytotoxic and could induce the apoptosis of tumor cells, prevent tumors from metastasizing and assist macrophage to kill tumor cells⁹. During recent years, NO-releasing derivatives have currently come into focus on the treatment of cancer, inflammation and vascular diseases^{10,11}.

Chang and his co-workers reported a group of nitrate derivatives of colchicine, which have proved that the structure modification of the 10 position does not interfere with the molecular recognition of colchicine¹². In our design, furoxans were substituted for organic nitrates acting as NO donors, because furoxans are supposed to be able to release higher concentrations of NO *in vivo* and can also effectively avoid "the nitrate tolerance"¹³. By releasing NO *in vivo*, we hope to enhance the antitumor activity of these derivatives and particularly to minimize the side effects.

The synthetic route of these target compounds is outlined in **Scheme-I**. Colchicine (**1**) was purchased from Nanjing Tianzun Chemicals Co. Ltd. China, with an over 98 % purity. The lead compound **3** was prepared from **1**, according to the literature¹⁴ in 85 % yield.

The synthesis of furoxans **7a-7j** utilized thiophenol **4** as the starting material, which was converted to 2-(phenylthio)acetic acid **5** by treatment with chloroacetic acid in 97 % yield. Compound **5** was oxidized by 30 % H₂O₂ solution, followed by treatment with fuming HNO₃ to offer diphenylsulfonylfuroxan **6**. Reaction of **6** with corresponding diols gave **7a-7j** with the yields of 65-85 %.

Scheme-I: Reagents and conditions: (a) 1. NaOH (aq.), ClCH₂COOH, 140 °C, 2 h; 2. 6N HCl, 97 %; (b) 1. 30 % H₂O₂, AcOH, rt, 3 h; 2. fuming HNO₃, 90 °C, 4 h; (c) HOROH, THF, 25 % NaOH, rt, 2 h, 65-85 %; (d) succinic anhydride, pyridine, 60 °C, 5 h, 90-95 %; (e) 3, EDC, DMAP, CH₂Cl₂, rt, 24 h, 60-85 %

Compounds **7a-7j** were acylated by succinic anhydride in dry pyridine at 60 °C to give succinates **8a-8j** in 90-95 % yield. Finally, **8a-8j** were treated with **3** in CH₂Cl₂ in the presence of EDC and DMAP to give target compounds **9a-9j** in good yields (60-85 %).

The resulting products were purified by column chromatography and their structures were shown in **Scheme-I** and the data of yield, MS, IR and ¹H NMR spectra and elemental analysis of selected compounds were shown in reference¹⁵.

The cytotoxic activity of all target compounds *in vitro* was determined by MTT assay¹⁶, using colchicine as a positive control and the result is summarized in Table-1. Four different cell lines were used: A2780 (human ovary cancer), A549

(human lung cancer), BEL7402 (human hepatoma), MCF7 (Human breast carcinoma).

The study results indicate that these novel nitric oxide-releasing derivatives showed superior or comparable cytotoxic activity to colchicine *in vitro*. For human ovary cancer cell line (A2780) and human lung cancer cell line (A549), all compounds exhibited weak inhibitory activity, except compound **9f**. In human hepatoma cell line (BEL7402), compounds **9b**, **9d**, **9e** and **9h** have similar cytotoxicity as colchicine, whereas compound **9f** has more potent cytotoxicity than colchicine. As to human breast carcinoma cell line (MCF7), compound **9f** exhibited almost tenfold potent activities than colchicine. The enhanced bioactivity suggested that the introduction of the furoxan group, which releases NO, did play a cooperative role in the exertion of antitumor activity, leading to a better balance between NO- and colchicine-dependent activity in the derivatives.

According to these cytotoxicity studies, it is suggested that different length of spacer arm in the hybrid compounds did have an impact on the molecules' capability to inhibit cancer cell growth to various degrees, but without showing significant difference on regular pharmacological behaviours.

In summary, a series of furoxan-based NO-donating colchicine derivatives were synthesized and evaluated for their *in vitro* cytotoxicity against four human tumor cell lines. Among all the derivatives, compound **9f** showed the strongest inhibitory activity against all the tested cell lines and it is currently under our further investigation.

TABLE-1
CYTOTOXICITY DATA OF THE TARGET COMPOUNDS

Compound	IC ₅₀ (μM)/cell line			
	A2780	A549	BEL7402	MCF7
9a	0.104	0.106	0.102	0.103
9b	0.098	0.087	0.080	0.135
9c	0.110	0.082	0.093	0.078
9d	0.096	0.086	0.079	0.100
9e	0.109	0.105	0.081	0.095
9f	0.045	0.035	0.012	0.008
9g	0.097	0.088	0.099	0.076
9h	0.096	0.079	0.083	0.088
9i	0.106	0.115	0.180	0.159
9j	0.100	0.106	0.130	0.104
Colchicine	0.094	0.078	0.080	0.084

REFERENCES

1. E. Niel, *Joint Bone Spine*, **73**, 672 (2006).
2. B. Bhattacharyya, D. Panda, S. Gupta and M. Banerjee, *Med. Res. Rev.*, **28**, 155 (2008).
3. A.D. Kinghorn, B.N. Su, D.S. Jang, L.C. Chang, D. Lee, J.Q. Gu, E.J. Carcache-Blanco, A.D. Pawlus, S.K. Lee, E.J. Park, M. Cuendet, J.J. Gills, K. Bhat, H.S. Park, E. Mata-Greenwood, L.L. Song, M. Jang and J.M. Pezzuto, *Planta Med.*, **70**, 691 (2004).
4. M. Cifuentes, B. Schilling, R. Ravindra, J. Winter and M.E. Janik, *Bioorg. Med. Chem. Lett.*, **16**, 2761 (2006).
5. C. Cerquaglia, M. Diaco, G. Nucera, M. La Regina, M. Montalto and R. Manna, *Curr. Drug Targets Inflamm. Allergy*, **4**, 117 (2005).
6. K.H. Lee, *J. Nat. Prod.*, **67**, 273 (2004).
7. P.G. Wang, M. Xian, X. Tang, X. Wu, Z. Wen, T. Cai and A.J. Janczuk, *Chem. Rev.*, **102**, 1091 (2002).
8. S. Pervin, G. Chaudhuri and R. Singh, *Curr. Pharm. Des.*, **16**, 451 (2010).
9. S. Mocellin, *Curr. Cancer Drug Targets*, **9**, 214 (2009).
10. T. Min, B. Yi, P. Zhang et al., *Med. Chem. Res.*, **18**, 495 (2009).
11. T. Wang, Y.H. Zhang, X.W. Kong, Y.S. Lai, H. Ji, Y.P. Chen and S.X. Peng, *Chem. Biodivers*, **6**, 466 (2009).
12. D.J. Chang, E.Y. Yoon, G.B. Lee, S.O. Kim, W.J. Kim, Y.M. Kim, J.W. Jung, H. An and Y.G. Suh, *Bioorg. Med. Chem. Lett.*, **19**, 4416 (2009).
13. L. Fang, Y.H. Zhang, J. Lehmann, Y. Wang, H. Ji and D. Ding, *Bioorg. Med. Chem. Lett.*, **17**, 1062 (2007).
14. L.H. Shen, Y. Li, D.H. Zhang, Y.S. Lai and L.J. Liu, *Chin. Chem. Lett.*, **22**, 768 (2011).
15. The data of selected compounds: **9a**: yield 60.0 %, IR (KBr, $\nu_{\max}$, cm^{-1}): 3436, 2929, 1736, 1623, 1553, 1450, 1387, 1170; ^1H NMR (CDCl_3 , 300 MHz, δ ppm): 1.50-3.38 (m, 9H), 3.07 (d, 3H, N-CH₃), 3.66 (s, 3H, MeO-1), 3.90 (s, 3H, MeO-2), 3.93 (s, 3H, MeO-3), 4.24-4.28 (t, 2H, $J = 6.0$ Hz, OCH₂), 4.44-4.48 (t, 2H, $J = 6.0$ Hz, OCH₂), 4.62-4.72 (m, 1H, H-7), 6.52 (s, 1H, H-4), 7.30 (m, 2H, Ar-H), 7.49 (s, 1H), 7.60-7.66 (m, 2H, ArH), 7.74-7.77 (m, 1H, ArH), 8.05-8.07 (m, 2H, ArH), 8.71 (bs, 1H, NHCO); MS (ESI, m/z): 724.3 $[\text{M}]^+$; anal. calcd. (%) for C₃₄H₃₆O₁₂N₄S: C 56.35, H 5.01, N 7.73; found (%): C 56.38, H 5.05, N 7.76. **9e**: yield 68.0 %, IR (KBr, $\nu_{\max}$, cm^{-1}): 3436, 2919, 1739, 1613, 1513, 1440, 1407, 1175; ^1H NMR (CDCl_3 , 300 MHz, δ ppm): 1.50-3.38 (m, 13H), 3.07 (d, 3H, N-CH₃), 3.67 (s, 3H, MeO-1), 3.91 (s, 3H, MeO-2), 3.95 (s, 3H, MeO-3), 4.25-4.29 (t, 2H, $J = 6.0$ Hz, OCH₂), 4.44-4.48 (t, 2H, $J = 6.0$ Hz, OCH₂), 4.65-4.72 (m, 1H, H-7), 6.54 (s, 1H, H-4), 7.27 (m, 2H, Ar-H), 7.48 (s, 1H), 7.61-7.66 (m, 2H, ArH), 7.74-7.79 (m, 1H, ArH), 8.04-8.06 (m, 2H, ArH), 8.93 (bs, 1H, NHCO); MS (ESI, m/z): 752.4 $[\text{M}]^+$; anal. calcd. (%) for C₃₆H₄₀O₁₂N₄S: C 57.44, H 5.36, N 7.44; found (%): C 57.55, H 5.40, N 7.49. **9f**: yield 60 %, IR (KBr, $\nu_{\max}$, cm^{-1}): 3438, 2929, 1719, 1623, 1503, 1445, 1368, 1145; ^1H NMR (CDCl_3 , 300 MHz, δ ppm): 1.50-3.36 (m, 9H), 3.07 (d, 3H, N-CH₃), 3.66 (s, 3H, MeO-1), 3.90 (s, 3H, MeO-2), 3.96 (s, 3H, MeO-3), 4.35 (d, 2H, $J = 5.4$ Hz, OCH₂), 5.15 (d, 2H, $J = 5.7$ Hz, OCH₂), 4.65-4.72 (m, 1H, H-7), 5.94-6.09 (m, 2H, -CH=CH-), 6.55 (s, 1H, H-4), 7.26 (m, 2H, Ar-H), 7.49 (s, 1H), 7.60-7.66 (m, 2H, ArH), 7.72-7.79 (m, 1H, ArH), 8.03-8.06 (m, 2H, ArH), 8.96 (bs, 1H, NHCO); MS (ESI, m/z): 750.2 $[\text{M}]^+$; anal. calcd. (%) for C₃₆H₃₈O₁₂N₄S: C 57.59, H 5.10, N 7.46; found (%): C 58.01, H 5.21, N 7.45. **9j**: yield 65 %, IR (KBr, $\nu_{\max}$, cm^{-1}): 3438, 2932, 1732, 1633, 1560, 1454, 1381, 1169; ^1H NMR (CDCl_3 , 300 MHz, δ ppm): 1.50-3.37 (m, 17H), 3.07 (d, 3H, N-CH₃), 3.65 (s, 3H, MeO-1), 3.90 (s, 3H, MeO-2), 3.94 (s, 3H, MeO-3), 4.24-4.28 (t, 2H, $J = 6.0$ Hz, OCH₂), 4.44-4.48 (t, 2H, $J = 6.0$ Hz, OCH₂), 4.64-4.72 (m, 1H, H-7), 6.50 (s, 1H, H-4), 7.34 (m, 2H, Ar-H), 7.47 (s, 1H), 7.62-7.67 (m, 2H, ArH), 7.75-7.78 (m, 1H, ArH), 8.05-8.07 (m, 2H, ArH), 9.07 (bs, 1H, NHCO); MS (ESI, m/z): 780.4 $[\text{M}]^+$; anal. calcd. (%) for C₃₈H₄₄O₁₂N₄S: C 58.45, H 5.68, N 7.18; found (%): C 58.48, H 5.65, N 7.15.
16. J. Tatsuzaki, M. Taniguchi, K.F. Bastow, K. Nakagawa-Goto, S.L. Morris-Natschke, H. Itokawa, K. Baba and K.H. Lee, *Bioorg. Med. Chem.*, **15**, 6193 (2007).